<p>(A) LOVO, (B) HCT116, (C) WIDR, and (D) GEO were plated in 6 well plates and exposed to single agent the PI3K/mTORi, PF-04691502, the MEKi, PD-0325901 or the combination for 72 hours. Drug was removed and replaced with media to allow for regrowth of clones. Cells were then stained with crystal violet and photographed. (E) The crystal violet was solubilized in 1% acetic acid and the absorbance was assessed on a plate reader. The data was normalized to control and graphed. All data presented as mean±SD, ANOVA Tukey’s adjusted p values: *<i>p</i>,0.05, **<i>p</i><0.01, ***<i>p</i><0.001 vs vehicle, #<i>p</i>,0.05, ##<i>p</i><0.01, ###<i>p</i><0.001 vs PF-502, &<i>p</i>,0.05, &&<i>p</i><0.01, &&&<i>p</i><0.001 vs PD-901. All data represents ...
The objective of tailoring medicines for cancer patients according to the molecular profile of their...
<p>PI3K p85/VEGFR-3 complexes (<i>red</i>) detected by <i>in situ</i> PLA in tumor cells and lymphat...
Background: Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (...
<p>LOVO (KRAS<sup>G13D</sup>), HCT116 (KRAS<sup>G13D</sup>/PIK3CA<sup>H1047R</sup>), WIDR (BRAF<sup>...
<p>Cells were plated in 96 well plates and allowed to adhere for 24 hours. Cells were exposed to inc...
<p>Cells were plated in 96 well plates and allowed to adhere for 24 hours. Cells were exposed to inc...
<p>The respective p-values are indicated. (A) Box plots of the Mann–Whitney <i>t</i>-test showing th...
Adaptive drug resistance is a major obstacle to successful treatment of colorectal cancers. Physiolo...
Combined targeting of the MAPK and PI3K signalling pathways in cancer may be necessary for optimal t...
Introduction: One of the main obstacle to the successful development of therapeutic strategies remai...
The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of cancers. Acti...
Background: The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of c...
<p><b>A.</b> Resistance to PI3Ki is correlated to increased pERK. Western blots of proteins isolated...
BACKGROUND: Combined targeting of MAPK and PI3K signalling pathways may be necessary for optimal the...
<p><b>A.</b> Changes in the cell cycle distribution of SW48 and HT-29 cells after 72 h of treatment ...
The objective of tailoring medicines for cancer patients according to the molecular profile of their...
<p>PI3K p85/VEGFR-3 complexes (<i>red</i>) detected by <i>in situ</i> PLA in tumor cells and lymphat...
Background: Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (...
<p>LOVO (KRAS<sup>G13D</sup>), HCT116 (KRAS<sup>G13D</sup>/PIK3CA<sup>H1047R</sup>), WIDR (BRAF<sup>...
<p>Cells were plated in 96 well plates and allowed to adhere for 24 hours. Cells were exposed to inc...
<p>Cells were plated in 96 well plates and allowed to adhere for 24 hours. Cells were exposed to inc...
<p>The respective p-values are indicated. (A) Box plots of the Mann–Whitney <i>t</i>-test showing th...
Adaptive drug resistance is a major obstacle to successful treatment of colorectal cancers. Physiolo...
Combined targeting of the MAPK and PI3K signalling pathways in cancer may be necessary for optimal t...
Introduction: One of the main obstacle to the successful development of therapeutic strategies remai...
The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of cancers. Acti...
Background: The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of c...
<p><b>A.</b> Resistance to PI3Ki is correlated to increased pERK. Western blots of proteins isolated...
BACKGROUND: Combined targeting of MAPK and PI3K signalling pathways may be necessary for optimal the...
<p><b>A.</b> Changes in the cell cycle distribution of SW48 and HT-29 cells after 72 h of treatment ...
The objective of tailoring medicines for cancer patients according to the molecular profile of their...
<p>PI3K p85/VEGFR-3 complexes (<i>red</i>) detected by <i>in situ</i> PLA in tumor cells and lymphat...
Background: Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (...